Please login to the form below

Not currently logged in
Email:
Password:

FDA warns on osteoporosis drugs

The US Food and Drug Administration has warned about a possible link between bisphosphonates and a type of thigh-bone fracture

The US Food and Drug Administration (FDA) has issued an alert about a possible link between the class of osteoporosis drugs known as bisphosphonates and a rare type of thigh-bone fracture. The agency said it will require a new warning on the drugs' labels, as well as a Risk Evaluation and Mitigation Strategy (REMS) that will consist mainly of a medication guide to be given to consumers along with their medication.

Bisphosphonates, which slow the loss of bone mass, have been marketed in the US for about 15 years. Oral drugs in the class include Warner Chilcott's Actonel (risedronate) and Atelvia (delayed-release risedronate), Genentech's Boniva (ibandronate), and Merck's Fosamax (alendronate), as well as generic versions of those products. Injectable bisphosphonates include Boniva and Novartis' Reclast (zoledronic acid).

The new medication guide for the osteoporosis drugs describes the symptoms of an atypical femur fracture and advises patients to notify their physicians if they develop the symptoms, which include a dull pain or ache in the hip or thigh.

The fractures reported in users of bisphosphonate for osteoporosis are known as subtrochanteric femur fractures, which occur just below the hip joint, and diaphyseal femur fractures, which occur in the long part of the thigh. The fractures may be related to use of bisphosphonates for longer than five years, the FDA noted.

In letters issued to the drugs' manufacturers requesting the labelling changes, the FDA pointed to "recent publications, including the 2010 report of a task force of the American Society for Bone and Mineral Research (that) suggest that the risk of atypical fractures…increases with increased duration of bisphosphonate exposure."

The FDA said it would continue to evaluate data on the possible link. The agency noted that labelling for bisphosphonates when they are used in other approved indications, such as multiple myeloma, is not being changed.

15th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics